HCM
HUTCHMED
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · HK
$13.67
−1.09%Aug 17, 2026, 07:03 UTC
AstraZeneca reported positive late-stage trial results for a combination of its lung cancer drugs Tagrisso and Orpathys, potentially paving the way for global approval.
Jul 2, 2026, 08:30 UTC
HUTCHMED received NMPA approval for ORPATHYS® for the treatment of gastric cancer patients with MET amplification in China.
Source: